Amarantus Therapeutics Announces Key Additions to Scientific Advisory Board

SUNNYVALE, Calif.--(BUSINESS WIRE)--

Amarantus Therapeutics, Inc. announced today that it has appointed two new members to its Scientific Advisory Board. Joining the panel are Dr. Eugene Johnson, Ph.D. Professor, Department of Developmental Biology at Washington University School of Medicine, and Dr. Greg Gerhardt, Ph.D., Professor of Anatomy and Neurobiology, Neurology, and Psychiatry, and Director, Morris K. Udall Parkinson’s Disease Research Center of Excellence at the University of Kentucky.

“Adding Drs. Johnson and Gerhardt to our SAB marks a significant step in the strategic development of our drug development platform and pipeline,” said Martin D. Cleary, Chairman and CEO of Amarantus Therapeutics. “The addition of these highly respected thought leaders significantly enhances our ability to develop more effective, better tolerated therapeutics and maximize research opportunities.”

Recognized in the scientific community as an authority on the biology of neurotrophic factors, Dr. Johnson is the Associate Director Alzheimer’s Disease Research Center and is a member of the Scientific Advisory Board of the Michael J. Fox Foundation and the AT Children’s Project. His research interests are in the mechanisms of neuronal cell death, neurodegenerative diseases, and the biology and pharmacology of neurotrophic factors. Dr. Johnson commented, “It is a great honor to serve on the advisory board for Amarantus, which is has already made significant progress in research to address the apoptotic pathway associated with a wide range of diseases.”

Dr. Gerhardt’s Udall Center focuses on the use of neurotrophic factors to repair damaged or dyeing dopamine neurons in Parkinson’s disease. His laboratory focuses on studies of the dopamine and glutamate neurotransmitter systems in animal models of Parkinson’s disease. Another area of research in his laboratory involves studies of movement abnormalities in aging and age-related changes in neurotransmitter signaling in the central nervous system. Dr. Gerhardt commented, “I am pleased to join the advisory board as Amarantus’ mission in drug development is closely aligned with our research focused on the development of treatments for Parkinson’s disease.”

Amarantus’ most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinson’s disease and Myocardial Infarction.

About Amarantus Therapeutics, Inc.

Amarantus Therapeutics, Inc. is a privately-held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. The Company’s most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinson’s disease and Myocardial Infarction. Currently incubating at the Parkinson’s Institute, Amarantus Therapeutics is seeking to raise a $1 million investment as a bridge to a $15 million Series A that it will use to advance its lead programs in Parkinson’s and Myocardial Infarction into clinical development. www.amarantustherapeutics.com